Zymeworks (ZYME) announced highlights from its R&D Day reviewing the Company’s development progress on its wholly-owned pipeline assets and expansion into new therapeutic areas in hematological cancers and autoimmune and inflammatory diseases. Company on track to deliver five Investigational New Drug applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original target; Nomination of ZW209, a novel trispecific T cell engager, as fifth development candidate in the Company’s solid tumor portfolio; Expansion into autoimmune and inflammatory diseases and hematology oncology leverages the Company’s clinically validated Azymetric technology platform and expertise in multispecific therapeutics; ZW1528, the Company’s first development candidate in AIID, demonstrates dual blockade of two complementary pathways of respiratory inflammation and offers potential benefit in mixed-type chronic obstructive pulmonary disease
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZYME:
- Zymeworks to Showcase Innovations at Investor Conferences
- Zymeworks Secures FDA Approval for Ziihera
- Zymeworks, Jazz Pharmaceuticals announce FDA approval of Ziihera
- JPMorgan, Five Below downgraded: Wall Street’s top analyst calls
- Zymeworks upgraded to Outperform from Market Perform at Leerink
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
